Institute of Infectious Diseases, Southwest Hospital, The Third Military Medical University, Chongqing 400038, China.
Gastroenterol Res Pract. 2012;2012:302093. doi: 10.1155/2012/302093. Epub 2012 Dec 3.
Background. The purpose of this study was to assess the efficacy and safety of low-dose peg-IFN α-2a plus ribavirin on the treatment of patients with chronic hepatitis C virus (HCV) infection. Patients and Methods. A total of 243 HCV patients treated with different doses of peg-IFN α-2a plus ribavirin were stratified into three groups. End-of-treatment response (ETR) and sustained viral response (SVR) were evaluated for efficacy. Adverse events and laboratory abnormalities were conducted for safety. Results. ETR and SVR in group I were obtained in 83.9% and 68.9% of the patients, separately, which was similar to groups II (84.1% and 68.3%) and III (81.7% and 66.7%). The received peg-IFN α-2a dose was not the independent factor-related SVR in our population (OR, 1.31; 95% CI, 0.94-1.81; P = 0.106). The frequency of no adverse events reported in group III (24.7%) was significantly higher than that in group I (11.5%) and group II (12.7%) (P = 0.036). Conclusions. The peg-IFN α-2a 90 μg/week plus ribavirin is as effective as, and better tolerated than, peg-IFN α-2a standard dose with ribavirin in the treatment of chronic hepatitis C. This low-dose combination achieves high SVR rates and may be cost-saving.
本研究旨在评估低剂量聚乙二醇干扰素 α-2a 联合利巴韦林治疗慢性丙型肝炎病毒（HCV）感染患者的疗效和安全性。
将接受不同剂量聚乙二醇干扰素 α-2a 联合利巴韦林治疗的 243 例 HCV 患者分层为三组。评估治疗结束时应答（ETR）和持续病毒应答（SVR）以评估疗效。评估不良事件和实验室异常以评估安全性。
I 组的 ETR 和 SVR 分别为 83.9%和 68.9%，与 II 组（84.1%和 68.3%）和 III 组（81.7%和 66.7%）相似。我们人群中 SVR 的独立因素与接受的聚乙二醇干扰素 α-2a 剂量无关（OR，1.31；95%CI，0.94-1.81；P = 0.106）。III 组（24.7%）报告的无不良事件的频率明显高于 I 组（11.5%）和 II 组（12.7%）（P = 0.036）。
聚乙二醇干扰素 α-2a 90μg/周联合利巴韦林与聚乙二醇干扰素 α-2a 标准剂量联合利巴韦林治疗慢性丙型肝炎的疗效相当，且耐受性更好。这种低剂量联合方案可实现高 SVR 率，并且可能节省成本。
